OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Mean Cell Volume Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,526 reports · 47 co-occurring drugs

As of the last recalculation, Mean Cell Volume Decreased appears in 1,526 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 47.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Alemtuzumab6547.848.0
Dimenhydrinate3545.846.0
Diclofenac Potassium, Film Coated2744.544.7
Diclofenac Potassium Tablets2744.544.6
Clozapine32143.944.0
Diclofenac Potassium2734.734.8
Calcium Gluconate2832.332.3
Cortisone Acetate2730.330.4
Adalimumab-Fkjp8727.127.2
Adalimumab-Aaty8726.526.6
Adalimumab-Adaz8723.823.8
Sulfasalazine12022.622.7
Leflunomide14520.820.8
Hydroxychloroquine Sulfate11518.518.6
Desoximetasone2518.218.2
Methimazole1017.517.5
Tocilizumab13016.916.9
Infliximab-Dyyb2913.813.8
Diclofenac Sodium 1%3513.713.7
Diclofenac Sodium Topical3513.713.7
Diclofenac Sodium Topical Gel, 1%3513.613.6
Abatacept11412.112.1
Pseudoephedrine Hydrochloride912.012.0
Trimethoprim1011.611.6
Pseudoephedrine Hcl911.211.2
Aripiprazole Oral3311.111.1
Aripiprazole Orally Disintegrating3311.111.1
Nicotine Polacrilex Mini1211.011.0
Nicotine Polarilex1211.011.0
Labetalol1010.310.3
Cetirizine Hydrochloride Allergy2210.010.0
Cetirizine Hydrochloride Tablets2210.010.0
Infliximab1429.79.7
Rituximab1339.39.3
Paliperidone148.38.3
Entecavir78.28.2
Niraparib116.86.8
Iohexol46.66.6
Tofacitinib Citrate66.36.3
Methoxy Polyethylene Glycol-Epoetin Beta56.26.2
Nicotine Polacrilex155.45.4
Crizotinib55.45.4
Golimumab325.25.2
Certolizumab Pegol344.04.0
Somatropin203.73.7
Dalfampridine193.63.6
Droxidopa31.91.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.